Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
12
2
2
3
3
3
Research & Development
42
6
5
23
7
8
Operating Expenses
56
9
8
27
10
12
Other Non Operating Income (Expenses)
1
0
0
0
0
0
Pretax Income
-55
-9
-8
-26
-10
-11
Income Tax Expense
0
0
--
--
--
--
Net Income
-55
-9
-8
-26
-10
-11
Net Income Growth
0%
-18%
-27%
73%
-41%
-21%
Shares Outstanding (Diluted)
3.98
3.98
2.67
2.37
2.33
2.33
Shares Change (YoY)
71%
71%
15%
2%
0%
0%
EPS (Diluted)
-14.02
-2.37
-3.22
-11.28
-4.7
-4.97
EPS Growth
-41%
-52%
-35%
76%
-36%
-20%
Free Cash Flow
-49
-7
-6
-22
-12
-6
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
-54
-9
-8
-27
-10
-12
EBITDA Margin
0%
0%
0%
0%
0%
0%
D&A For EBITDA
2
0
0
0
0
0
EBIT
-56
-9
-8
-27
-10
-12
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
0%
0%
--
--
--
--
Follow-Up Questions
What are NextCure Inc's key financial statements?
According to the latest financial statement (Form-10K), NextCure Inc has a total asset of $0, Net loss of $0
What are the key financial ratios for NXTC?
NextCure Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is NextCure Inc's revenue broken down by segment or geography?
NextCure Inc largest revenue segment is Skillz, at a revenue of 139,210,000 in the most earnings release.For geography, United States is the primary market for NextCure Inc, at a revenue of 133,479,999.
Is NextCure Inc profitable?
no, according to the latest financial statements, NextCure Inc has a net loss of $0
Does NextCure Inc have any liabilities?
no, NextCure Inc has liability of 0
How many outstanding shares for NextCure Inc?
NextCure Inc has a total outstanding shares of 0
Key Stats
Prev.Close
$10.25
Open
$9.78
Day's Range
$9.51 - $10.36
52 week range
$4.6 - $15.73
Volume
48.6K
Avg.Volume
43.7K
Dividend yield
--
EPS (TTM)
-21.58
Market Cap
$34.6M
What is NXTC?
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 40 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.